By Colin Kellaher

 

Sanofi SA on Friday said it has acquired Tidal Therapeutics, a preclinical-stage biotech startup using a novel mRNA-based approach for in-vivo reprogramming of immune cells, for an initial $160 million.

The Paris pharmaceutical giant said it could make up to an additional $310 in milestone payments as part of the deal, which it said expands its research capabilities in immuno-oncology and inflammatory diseases.

Sanofi said Tidal, based in Cambridge, Mass., uses a technology based on proprietary nanoparticles that deliver mRNA to reprogram immune cells inside the body. Tidal's current preclinical programs include in-vivo reprogramming of T-cells or other types of immune cells for cancer indications.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

April 09, 2021 14:16 ET (18:16 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Jun 2021 to Jul 2021 Click Here for more Sanofi Charts.
Sanofi (EU:SAN)
Historical Stock Chart
From Jul 2020 to Jul 2021 Click Here for more Sanofi Charts.